Header image

Program

Saturday, February 14, 2026

Laneway Room 1 & 2
Registration - Day 1
8:45 AM - 9:00 AM Opening Address
9:00 AM - 9:15 AM Cardio-metabolic Disorders as a Group
9:15 AM - 9:50 AM Models of care for cardiometabolic conditions: implications for future health systems
9:50 AM - 10:15 AM "Cardiovascular Metabolic Physician" - The birth of a new Generalist?'
10:15 AM - 10:45 AM Morning Tea - 14 February 2026
10:45 AM - 11:10 AM Managing Systemic Metabolic Disease in Patients Living with Obesity and CVD
11:10 AM - 11:35 AM Cardio-metabolic advances: GLP-1 RAs, SGLT2 Inhibitors and Non-Steroidal MRAs
11:35 AM - 12:00 PM Reimagining Blood Pressure Control via Gut-Driven Solutions
12:00 PM - 1:00 PM
Lunch - 14 February 2026
12:10 PM - 12:50 PM Sponsor Symposium - Novo Nordisk Pharmaceuticals
1:00 PM - 1:05 PM Introduction to Cardiovascular Epidemiology
1:05 PM - 1:25 PM Are we overlooking Primary Aldosteronism?
1:25 PM - 1:50 PM Obesity - a modifiable cardiovascular risk factor - state of play and future directions
1:50 PM - 2:15 PM AI in CVD prevention - test
2:15 PM - 2:50 PM
Afternoon Tea - 14 February 2026
2:50 PM - 3:15 PM CVD in Women
3:15 PM - 3:40 PM Triglycerides as a target for CVD
3:40 PM - 4:05 PM What are the key developments in hypertension in 2026?
4:05 PM - 5:00 PM Henry as a trialist
5:00 PM - 6:00 PM
4CC 2026 Conference Reception
Laneway Room 1 & 2
Registration - Day 1
8:45 AM - 9:00 AM Opening Address
9:00 AM - 9:15 AM Cardio-metabolic Disorders as a Group
9:15 AM - 9:50 AM Models of care for cardiometabolic conditions: implications for future health systems
9:50 AM - 10:15 AM "Cardiovascular Metabolic Physician" - The birth of a new Generalist?'
10:15 AM - 10:45 AM Morning Tea - 14 February 2026
10:45 AM - 11:10 AM Managing Systemic Metabolic Disease in Patients Living with Obesity and CVD
11:10 AM - 11:35 AM Cardio-metabolic advances: GLP-1 RAs, SGLT2 Inhibitors and Non-Steroidal MRAs
11:35 AM - 12:00 PM Reimagining Blood Pressure Control via Gut-Driven Solutions
12:00 PM - 1:00 PM
Lunch - 14 February 2026
12:10 PM - 12:50 PM Sponsor Symposium - Novo Nordisk Pharmaceuticals
1:00 PM - 1:05 PM Introduction to Cardiovascular Epidemiology
1:05 PM - 1:25 PM Are we overlooking Primary Aldosteronism?
1:25 PM - 1:50 PM Obesity - a modifiable cardiovascular risk factor - state of play and future directions
1:50 PM - 2:15 PM AI in CVD prevention - test
2:15 PM - 2:50 PM
Afternoon Tea - 14 February 2026
2:50 PM - 3:15 PM CVD in Women
3:15 PM - 3:40 PM Triglycerides as a target for CVD
3:40 PM - 4:05 PM What are the key developments in hypertension in 2026?
4:05 PM - 5:00 PM Henry as a trialist
5:00 PM - 6:00 PM
4CC 2026 Conference Reception

Laneway Room 1 & 2
Registration - Day 1
8:45 AM - 9:00 AM Opening Address
9:00 AM - 9:15 AM Cardio-metabolic Disorders as a Group
9:15 AM - 9:50 AM Models of care for cardiometabolic conditions: implications for future health systems
9:50 AM - 10:15 AM "Cardiovascular Metabolic Physician" - The birth of a new Generalist?'
10:15 AM - 10:45 AM Morning Tea - 14 February 2026
10:45 AM - 11:10 AM Managing Systemic Metabolic Disease in Patients Living with Obesity and CVD
11:10 AM - 11:35 AM Cardio-metabolic advances: GLP-1 RAs, SGLT2 Inhibitors and Non-Steroidal MRAs
11:35 AM - 12:00 PM Reimagining Blood Pressure Control via Gut-Driven Solutions
12:00 PM - 1:00 PM
Lunch - 14 February 2026
12:10 PM - 12:50 PM Sponsor Symposium - Novo Nordisk Pharmaceuticals
1:00 PM - 1:05 PM Introduction to Cardiovascular Epidemiology
1:05 PM - 1:25 PM Are we overlooking Primary Aldosteronism?
1:25 PM - 1:50 PM Obesity - a modifiable cardiovascular risk factor - state of play and future directions
1:50 PM - 2:15 PM AI in CVD prevention - test
2:15 PM - 2:50 PM
Afternoon Tea - 14 February 2026
2:50 PM - 3:15 PM CVD in Women
3:15 PM - 3:40 PM Triglycerides as a target for CVD
3:40 PM - 4:05 PM What are the key developments in hypertension in 2026?
4:05 PM - 5:00 PM Henry as a trialist
5:00 PM - 6:00 PM
4CC 2026 Conference Reception

Sunday, February 15, 2026

Laneway Room 1 & 2
Registration - Day 2
9:00 AM - 9:05 AM Day two open and introduciton to speakers in the Intervention and EP
9:05 AM - 9:40 AM Ectopic Beats and Myopathies: The Established & the Emerging
9:40 AM - 10:15 AM Angina with no Obstructive Coronary Artery Disease (ANOCA)
10:15 AM - 10:45 AM
Morning Tea - 15 February 2026
10:45 AM - 11:10 AM AF and Heart Failure: the chicken or the egg
11:10 AM - 11:35 AM Transforming Secondary Prevention After Myocardial Infarction – Insights from Plaque Imaging
11:35 AM - 12:00 PM Atrial Fibrillation Villain or Bystander
12:00 PM - 1:00 PM
Lunch - 15 February 2026
12:10 PM - 12:50 PM Sponsor Symposium - GSK
1:00 PM - 1:05 PM Heart Failure - Introduction
1:05 PM - 1:30 PM Big Data Insights to Structural Heart Disease with AI Solutions
1:30 PM - 1:55 PM Multi-Disciplinary Teams In Heart Failure Management – I Get By With A Little Help From My Friends
1:55 PM - 2:20 PM HF classification: Is it time to move beyond LVEF?
2:20 PM - 2:50 PM
Afternoon Tea - 15 February 2026
2:50 PM - 3:15 PM Obesity and heart failure: is this now a treatment target?
3:15 PM - 3:40 PM Beyond 4 pillars in HFrEF: What should I do next?
3:40 PM - 4:25 PM Heart Failure Keynote Lecture- What's new in drugs and devices for heart failure ?
4:25 PM - 4:35 PM Closing Address
Laneway Room 1 & 2
Registration - Day 2
9:00 AM - 9:05 AM Day two open and introduciton to speakers in the Intervention and EP
9:05 AM - 9:40 AM Ectopic Beats and Myopathies: The Established & the Emerging
9:40 AM - 10:15 AM Angina with no Obstructive Coronary Artery Disease (ANOCA)
10:15 AM - 10:45 AM
Morning Tea - 15 February 2026
10:45 AM - 11:10 AM AF and Heart Failure: the chicken or the egg
11:10 AM - 11:35 AM Transforming Secondary Prevention After Myocardial Infarction – Insights from Plaque Imaging
11:35 AM - 12:00 PM Atrial Fibrillation Villain or Bystander
12:00 PM - 1:00 PM
Lunch - 15 February 2026
12:10 PM - 12:50 PM Sponsor Symposium - GSK
1:00 PM - 1:05 PM Heart Failure - Introduction
1:05 PM - 1:30 PM Big Data Insights to Structural Heart Disease with AI Solutions
1:30 PM - 1:55 PM Multi-Disciplinary Teams In Heart Failure Management – I Get By With A Little Help From My Friends
1:55 PM - 2:20 PM HF classification: Is it time to move beyond LVEF?
2:20 PM - 2:50 PM
Afternoon Tea - 15 February 2026
2:50 PM - 3:15 PM Obesity and heart failure: is this now a treatment target?
3:15 PM - 3:40 PM Beyond 4 pillars in HFrEF: What should I do next?
3:40 PM - 4:25 PM Heart Failure Keynote Lecture- What's new in drugs and devices for heart failure ?
4:25 PM - 4:35 PM Closing Address

Laneway Room 1 & 2
Registration - Day 2
9:00 AM - 9:05 AM Day two open and introduciton to speakers in the Intervention and EP
9:05 AM - 9:40 AM Ectopic Beats and Myopathies: The Established & the Emerging
9:40 AM - 10:15 AM Angina with no Obstructive Coronary Artery Disease (ANOCA)
10:15 AM - 10:45 AM
Morning Tea - 15 February 2026
10:45 AM - 11:10 AM AF and Heart Failure: the chicken or the egg
11:10 AM - 11:35 AM Transforming Secondary Prevention After Myocardial Infarction – Insights from Plaque Imaging
11:35 AM - 12:00 PM Atrial Fibrillation Villain or Bystander
12:00 PM - 1:00 PM
Lunch - 15 February 2026
12:10 PM - 12:50 PM Sponsor Symposium - GSK
1:00 PM - 1:05 PM Heart Failure - Introduction
1:05 PM - 1:30 PM Big Data Insights to Structural Heart Disease with AI Solutions
1:30 PM - 1:55 PM Multi-Disciplinary Teams In Heart Failure Management – I Get By With A Little Help From My Friends
1:55 PM - 2:20 PM HF classification: Is it time to move beyond LVEF?
2:20 PM - 2:50 PM
Afternoon Tea - 15 February 2026
2:50 PM - 3:15 PM Obesity and heart failure: is this now a treatment target?
3:15 PM - 3:40 PM Beyond 4 pillars in HFrEF: What should I do next?
3:40 PM - 4:25 PM Heart Failure Keynote Lecture- What's new in drugs and devices for heart failure ?
4:25 PM - 4:35 PM Closing Address

Footer image
loading